Sarepta Therapeutics, Inc., a commercial-stage biopharmaceutical company, focuses on the discovery and development of RNA-targeted therapeutics, siRNA platform, gene therapy, and other genetic therapeutic modalities for the treatment of rare diseases. It offers EXONDYS 51 for the treatment of Duchenne in patients who have a confirmed mutation of the dystrophin gene that is amenable to exon 51 skipping; VYONDYS 53 for the treatment of Duchenne in patients who have a confirmed mutation of the dystrophin gene that is amenable to exon 53 skipping; AMONDYS 45 for the treatment of Duchenne in patients who have a confirmed mutation of the dystrophin gene that is amenable to exon 45 skipping; and ELEVIDYS, an AAV-based gene therapy, which is contraindicated in patients with any deletion in exon 8 and/or exon 9 in the Duchenne gene. The company also develops SRP-9003, a gene therapy program for the treatment of LGMD2E; SRP-1001 to selectively target and knockdown DUX4 using RNAi in Phase 1/2a clinical trials; and SRP-1003 for reduction of expression of the DMPK gene in Phase 1/2a clinical trials. It has collaboration and license agreements with F. Hoffman-La Roche Ltd; Arrowhead Pharmaceuticals, Inc.; University of Western Australia; Nationwide Children's Hospital; Hansa Biopharma; and Duke University. The company was incorporated in 1980 and is headquartered in Cambridge, Massachusetts.…
DraftKings downgraded, Sarepta upgraded: Wall Street's top analyst calls
Sarepta Therapeutics (NASDAQ: SRPT) is listed on Nasdaq, where its shares trade in USD. It belongs to the Biotechnology industry, part of the Healthcare sector, and reports about 835 employees.
The shares were at 13.33 USD on 20 November 2026, down 24.4% over 52 weeks. Its 52-week range is 13.25 USD to 24.68 USD, and it trades at the bottom of that range.
Its market capitalisation is 1.43B USD.
Sarepta Therapeutics reports return on equity of -62.5%, an operating margin of -0.4% and revenue down 4.5% year over year.
Its debt exceeds its cash by 200.28M USD, a debt-to-equity ratio of 0.91. Its Piotroski F-score is 3 out of 9, a weak reading of its financial health. 22 analysts cover the stock, with an average rating of Hold; their mean price target of 21.86 USD is 64.0% above the current price. The next earnings report is expected on 24 February 2027.